These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 8742106)
1. Correlation between sensitivity in vitro of patient chronic lymphocytic leukemia cells and clinical systemic exposure at the maximum tolerated dose for cell cycle phase-specific (type 2) anticancer drugs. Fridborg H; Nygren N; Larsson R Anticancer Drugs; 1996 Jan; 7(1):105-8. PubMed ID: 8742106 [TBL] [Abstract][Full Text] [Related]
2. Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Fridborg H; Nygren P; Larsson R Anticancer Drugs; 1995 Feb; 6(1):64-9. PubMed ID: 7756685 [TBL] [Abstract][Full Text] [Related]
3. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. Fuse E; Kobayashi S; Inaba M; Suzuki H; Sugiyama Y J Natl Cancer Inst; 1994 Jul; 86(13):989-96. PubMed ID: 8024657 [TBL] [Abstract][Full Text] [Related]
4. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167 [TBL] [Abstract][Full Text] [Related]
6. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells. Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986 [TBL] [Abstract][Full Text] [Related]
7. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439 [TBL] [Abstract][Full Text] [Related]
8. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743 [TBL] [Abstract][Full Text] [Related]
10. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Morabito F; Callea I; Console G; Stelitano C; Sculli G; Filangeri M; Oliva B; Musolino C; Iacopino P; Brugiatelli M Haematologica; 1997; 82(5):560-5. PubMed ID: 9407721 [TBL] [Abstract][Full Text] [Related]
11. Selective toxicity of persian gulf sea cucumber holothuria parva on human chronic lymphocytic leukemia b lymphocytes by direct mitochondrial targeting. Salimi A; Motallebi A; Ayatollahi M; Seydi E; Mohseni AR; Nazemi M; Pourahmad J Environ Toxicol; 2017 Apr; 32(4):1158-1169. PubMed ID: 27404045 [TBL] [Abstract][Full Text] [Related]
13. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay. Morabito F; Messina G; Oliva B; Ramirez F; Callea V; Brugiatelli M; Nobile F Haematologica; 1993; 78(4):213-8. PubMed ID: 8294052 [TBL] [Abstract][Full Text] [Related]
14. Relationships of in vitro sensitivities tested with nine drugs and two types of irradiation in chronic lymphocytic leukemia. Kivekäs I; Vilpo L; Vilpo J Leuk Res; 2002 Nov; 26(11):1035-41. PubMed ID: 12363473 [TBL] [Abstract][Full Text] [Related]
15. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours. Larsson R; Fridborg H; Liliemark J; Csoka K; Kristensen J; de la Torre M; Nygren P Eur J Cancer; 1994; 30A(7):1022-6. PubMed ID: 7946567 [TBL] [Abstract][Full Text] [Related]
17. Selective toxicity of vincristine against chronic lymphocytic leukaemia in vitro. The Tampere CLL Group. Vilpo J; Vilpo L Lancet; 1996 May; 347(9013):1491-2. PubMed ID: 8676665 [No Abstract] [Full Text] [Related]
19. Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Frankfurt OS; Byrnes JJ; Seckinger D; Sugarbaker EV Oncol Res; 1993; 5(1):37-42. PubMed ID: 8369574 [TBL] [Abstract][Full Text] [Related]
20. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]